Orion Pharma Animal Health News and Activities

Orion Pharma Animal Health is owned by Orion Pharma.

Orion Pharma is one of the...

• Stoxx 600;
• TOB Iconic 10,000.

Orion Pharma is a company listed under the stock ticker ORINY (FI).

They are in:

• Pharmaceuticals67%
• Biotechnology33%

View the org chart displaying its 8 main executives

Most searched biographies at Orion Pharma Animal Health

• Niclas Lindstedt, Senior Vice President
• Simon Boulton, Global Marketing Director
• Jon Engeseth, Head, Nordics and Central Eastern Europe

Popular executive movements at Orion Pharma

• Christina Villumsen has joined the company as Vice President, Corporate Communications, Brand and Public Affairs  (posted on April 27 2026).
• Berkeley Vincent will join the company as Executive Vice President, Innovative Medicines on Apr. 8, 2026  (posted on April 1 2026).
• Outi Vaarala who was Senior Vice President, Innovative Medicines and Research & Development, becomes Senior Vice President, Research & Development  (posted on April 1 2026).

Click here to view some more movements at Orion Pharma

Create your alert
to follow the executive moves at Orion Pharma Animal Health.

Orion Pharma has 2,426 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• Archimed Group has acquired Esperion Therapeutics (posted on July 14 2026).
• The new name of ChemoTech is Neem’s Hill. (posted on July 14 2026).
• MindRank has just announced a $52 Million fundraising (posted on July 14 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Robert Gould - Board Member at Fulcrum Therapeutics

Learn more about the Biotechnology industry

Press releases by Orion Pharma Animal Health

• Orion publishes Half-Year Report for January–June 2026 and holds a webcast on 17 July 2026
• Orion Pharma announces agreement with Shilpa Medicare for nivolumab biosimilar for European market
• Orion Pharma’s ODM-212 Granted Orphan Designation for the Treatment of Malignant Mesothelioma by the European Commission
• The Veturi research ecosystem led by Orion: Personalised medicine is now advancing rapidly
• Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid tumours
• Orion Pharma to present its first clinical data from Phase 1/2 TEADES trial of TEAD inhibitor ODM-212 at the 2026 ASCO® Annual Meeting
• 105,950 Orion Corporation A shares converted into B shares
• Orion Animal Health receives US FDA approval for Tessie® (tasipimidine oral solution) for the treatment of noise aversion and separation anxiety in dogs
• A stable society does not appear out of the blue – Orion and CMI open discussions about lasting peace in an evolving world
• Early diagnosis gives better outcomes – Taking control of asthma from the start
• View more press releases Close

Social media about Orion Pharma Animal Health

• Orion Pharma Animal Health on Wikipedia, Google News & Yahoo Finance
• Orion Pharma Animal Health on LinkedIn, X (Twitter) & YouTube